Haemonetics Corporation announced the appointment of Frank W. Chan, Ph.D., as Executive Vice President and Chief Operating Officer, effective April 7, 2025. Mr. Chan will oversee research and development, regulatory affairs, and global manufacturing and supply chain functions, reporting directly to CEO Christopher A. Simon. Mr. Chan brings over 25 years of leadership experience in the medical device and healthcare technology sectors, most recently serving as President of the Acute Care & Monitoring business at Medtronic.

As part of his compensation, Mr. Chan will receive an annual base salary of $550,000, a target annual bonus of 80% of his salary, and a long-term incentive equity award valued at $1.6 million. He will also receive a $350,000 sign-on bonus, with repayment conditions tied to tenure.

Additionally, Haemonetics announced the promotion of Roy Galvin, President of Global Plasma and Blood Center, to Executive Vice President and Chief Commercial Officer, where he will oversee the commercialization of the company's full product portfolio. Stewart Strong, President of Global Hospital, will remain in his current role until April 1, 2025, before transitioning to an advisory position.

A press release detailing these leadership changes was issued on March 3, 2025.